Abstract:An increase in α-synuclein (α-syn) levels and mutations in proteins associated with mitochondria contribute to the development of familial Parkinson's disease (PD); however, the involvement of α-syn and mitochondria in idiopathic PD remains incompletely understood. The voltage-dependent anion channel I (VDAC1) protein, which serves as a crucial regulator of mitochondrial function and a gatekeeper, plays a pivotal role in governing cellular destiny through the control of ion and respiratory metabolite flux. The ability of resveratrol (RES), which is a potent phytoalexin with antioxidant and anti-inflammatory properties, to regulate VDAC1 in PD is unknown. The objective of this study was to evaluate the role of VDAC1 in the pathological process of PD and to explore the mechanism by which resveratrol protects dopaminergic neurons by regulating VDAC1 to maintain the mitochondrial permeability transition pore (mPTP) and calcium ion balance. The effects of RES on the motor and cognitive abilities of A53T mice were evaluated by using small animal behavioral tests. Various techniques, including immunofluorescence staining, transmission electron microscopy, enzyme-linked immunoadsorption, quantitative polymerase chain reaction (PCR), and Western blotting, among others, were employed to assess the therapeutic impact of RES on neuropathy associated with PD and its potential in regulating mitochondrial VDAC1. The findings showed that RES significantly improved motor and cognitive dysfunction and restored mitochondrial function, thus reducing oxidative stress levels in A53T mice. A significant positive correlation was observed between the protein expression level of VDAC1 and mitochondrial α-syn expression, as well as disease progression, whereas no such correlation was found in VDAC2 and VDAC3. Administration of RES resulted in a significant decrease in the protein expression of VDAC1 and in the protein expression of α-syn both in vivo and in vitro. In addition, we found that RES prevents excessive opening of the mPTP in dopaminergic neurons. This may prevent the abnormal aggregation of α-syn in mitochondria and the release of mitochondrial apoptosis signals. Furthermore, the activation of VDAC1 reversed the resveratrol-induced decrease in the accumulation of α-syn in the mitochondria. These findings highlight the potential of VDAC1 as a therapeutic target for PD and identify the mechanism by which resveratrol alleviates PD-related pathology by modulating mitochondrial VDAC1.

VDR and deubiquitination control neuronal oxidative stress and microglial inflammation in Parkinson's disease

E3 Ubiquitin Ligase TRIM31 Alleviates Dopaminergic Neurodegeneration by Promoting Proteasomal Degradation of VDAC1 in Parkinson’s Disease Model

Resveratrol Inhibits VDAC1-Mediated Mitochondrial Dysfunction to Mitigate Pathological Progression in Parkinson's Disease Model

E3 ubiquitin ligase TRIM31 alleviates dopaminergic neurodegeneration by promoting proteasomal degradation of VDAC1 in Parkinson's Disease model

Brain Endothelial P-Glycoprotein Level Is Reduced in Parkinson’s Disease via a Vitamin D Receptor-Dependent Pathway

Reduced Nicotinamide Adenine Dinucleotide Phosphate Inhibits MPTP-Induced Neuroinflammation and Neurotoxicity

PGC-1α/ERRα-Sirt3 Pathway Regulates DAergic Neuronal Death by Directly Deacetylating SOD2 and ATP Synthase β

Vps35 Regulates Cell Surface Recycling and Signaling of Dopamine Receptor D1

4,4′-Dimethoxychalcone Regulates Redox Homeostasis by Targeting Riboflavin Metabolism in Parkinson's Disease Therapy

The Relationships of Vitamin D, Vitamin D Receptor Gene Polymorphisms, and Vitamin D Supplementation with Parkinson’s Disease

Vitamin D Treatment Attenuates Neuroinflammation and Dopaminergic Neurodegeneration in an Animal Model of Parkinson’s Disease, Shifting M1 to M2 Microglia Responses

The Potential Role of Voltage-Dependent Anion Channel in the Treatment of Parkinson's Disease

PDCD4 Triggers Α-Synuclein Accumulation and Motor Deficits Via Co-Suppressing TFE3 and TFEB Translation in a Model of Parkinson’s Disease

The Potential Role of Voltage-Dependent Anion Channel in the Treatment of Parkinson’s Disease

Pyridoxine induces glutathione synthesis via PKM2-mediated Nrf2 transactivation and confers neuroprotection

VDR promotes nucleus pulposus cell mitophagy as a protective mechanism against oxidative stress injury

Potential Implications of Mitochondrial Unfolded Protein Response in the Pathogenesis and Therapy of Dopaminergic Neuron Degeneration in Parkinson ’ s Disease

Overexpression of Thioredoxin Reductase 1 Can Reduce DNA Damage, Mitochondrial Autophagy and Endoplasmic Reticulum Stress in Parkinson's Disease

Di-Dang-Tang ameliorates cognitive dysfunction in vascular dementia rats via inhibition of ferroptosis through PGK1/NRF2/GPX4 Signaling Pathway

Chronic vitamin D3 supplementation alleviates cognition impairment via inhibition of oxidative stress regulated by PI3K/AKT/Nrf2 in APP/PS1 transgenic mice

Midbrain dopamine oxidation links ubiquitination of glutathione peroxidase 4 to ferroptosis of dopaminergic neurons